Table 3.

ORs (95% CI) of various risk factors in relation to neonatal and neurodevelopmental outcomes, using univariate and multiple regression analyses

	All infants	Perinatal anemia	Non-anemic
Adverse outcome, na	111	23	88
Univariate regression analysis
Hb pp, mmol/L	1.09 (0.94–1.25)#	0.80 (0.50–1.26)#	1.40 (1.04–1.87)*
Apgar score 5th min	0.91 (0.75–1.10)	0.68 (0.43–1.07)	0.98 (0.77–1.25)
Lactate 1 h pp, mmol/L	1.07 (1.01–1.24)*	1.19 (1.00–1.41)*	1.05 (0.98–1.12)#
PNA at start TH, h	1.10 (0.86–1.41)	2.02 (0.93–4.38)	0.98 (0.73–1.30)
Multiple regression analysis
Hb pp, mmol/L	1.11 (0.96–1.29)	0.90 (0.53–1.53)	1.39 (1.03–1.86)*
Mortality, n	111	23	88
Univariate regression analysis
Hb pp, mmol/L	0.89 (0.76–1.04)#	0.80 (0.50–1.26)#	1.35 (0.94–1.93)#
Apgar score 5th min	0.62 (0.48–0.81)*	0.68 (0.43–1.07)#	0.65 (0.47–0.89)*
Lactate 1 h pp, mmol/L	1.11 (1.03–1.19)*	1.19 (1.00–1.41)*	1.09 (1.00–1.18)*
PNA at start TH, h	0.98 (0.74–1.29)	2.02 (0.93–4.38)	0.92 (0.65–1.30)
Multiple regression analysis
Hb pp, mmol/L	0.97 (0.81–1.15)	0.88 (0.51–1.53)	1.34 (0.91–1.96)
Abnormal NDO, n	81	b	69
Univariate regression analysis
Hb pp, mmol/L	1.53 (1.14–2.07)*		1.34 (0.95–1.89)#
Apgar score 5th min	1.29 (0.97–1.72)#		1.30 (0.94–1.79)#
Lactate 1 h pp, mmol/L	1.01 (0.94–1.09)		1.01 (0.93–1.09)
PNA at start TH, h	1.17 (0.86–1.59)		1.02 (0.73–1.43)
Multiple regression analysis
Hb pp, mmol/L	1.54 (1.13–2.10)*		1.35 (0.95–1.92)

NDO, neurodevelopmental outcome; Hb, hemoglobin; pp, postpartum; PNA, postnatal age; TH, therapeutic hypothermia.

^*p < 0.05;

^#p < 0.20.

^aAdverse outcome indicates death or abnormal neurodevelopmental outcome.

^bNo infants with perinatal anemia had an abnormal NDO. Therefore, we did not perform separate logistic regression analyses for abnormal NDO in anemic infants.